Skip to content

About
Mission

Guiding Principles

Collaborations & Partnerships

Solid Team

Management

Board of Directors

Duchenne Scientific Advisory Board

Founders

Working at Solid

Culture

Benefits

Open Positions
Our Science
Pipeline & Programs

Pipeline

Scientific Publications & Presentations

Infrastructure

Manufacturing
Patient & Caregiver Resources
Duchenne Muscular Dystrophy

What is Duchenne?

Why Gene Transfer?

Duchenne Patient Stories

Friedreich’s Ataxia Resources

Friedreich’s Ataxia

What is Frataxin?

For Patients

Strength in Community

Engaging the Community

Charity Partners

Insights & News

Resources & Policies

Expanded Access Policy

Clinical Trials
Investors & Media
Overview & News

Overview

Press Releases

Presentations

Events

Governance & Financials

Governance Documents

Committee Charters

Committee Composition

SEC Filings

Stock Information

Stock Quote Chart

Historical Price Lookup

Analyst Coverage

Investor Resources

Investor FAQs

Contact Solid Biosciences

Email Alerts

Efficacy and Safety of a Novel AAV FXN Gene Therapy (AVB-202) for the Treatment of Friedreich’s Ataxia

Search

Recent Posts

Letter to the Duchenne Community – INSPIRE DUCHENNE Positive Initial Clinical Trial Data
Letter to the FA Community
Letter to the Duchenne Community – INSPIRE DUCHENNE update & expansion
Letter to the Duchenne Community – INSPIRE DUCHENNE update
Letter to the Duchenne Community

Recent Comments

No comments to show.

Stay Connected

Linkedin X-twitter

Join our team of experts to advance treatments for patients

Contact Us
Privacy Policy
Terms & Conditions

Contact Us
Privacy Policy
Terms & Conditions

© 2024 Solid Biosciences Inc. All Rights Reserved.

Solid Biosciences Inc., is a Charlestown, MA based life science company focused on advancing a portfolio of neuromuscular and cardiac programs.

The characterization of the discovery and development efforts on this website, as well as the expectations associated with them, are reflective of the current state of development and may change as the Company progresses.